<DOC>
	<DOCNO>NCT01971918</DOCNO>
	<brief_summary>The objective study evaluate two therapeutic strategy : `` early switch '' `` therapeutic intensification '' patient spondyloarthritis case secondary treatment failure suspicion first monoclonal antibody anti-TNF definite increase ASDAS positivity ADAb . Patients Methods : Multicentric randomize prospective study . Duration inclusion 30 month . Duration follow-up 24 month . 104 patient spondyloarthritis treat infliximab adalimumab include ADAb dosage positive , randomize ( 1:1 ) two group : `` early switch '' treatment change another anti-TNF , `` therapeutic intensification '' interval two injection shorten . Patients evaluate clinically ( ASDAS ) biologically ( ADAb ) 12 week 24 week . Principal outcome variation ASDAS baseline end study . Number patient include determine statistically preliminary study ( power &gt; 98 % ASDAS variation 20 % week 24 ) . Expected result : On week 24 , expect good response great proportion patient remission `` early switch '' arm compare `` therapeutic intensification '' arm .</brief_summary>
	<brief_title>Comparative Analysis Two Therapeutic Strategies Patients With Spondyloarthritis Treated With Anti-tnf Biologics</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antibodies , Anti-Idiotypic</mesh_term>
	<criteria>Spondyloarthritis positive ASAS criterion , treat first biologic : infliximab ( 5mg/kg intravenously every 8 week ) adalimumab ( 40mg subcutaneously every 2 week ) Active spondyloarthritis definite ASDASCRP &gt; 2.1 two successive evaluation patient previously responder ( ASDAS &lt; 2.1 least 6th month begin treatment ) Positivity antidrug antibody ( ADAb ) Consent patient No contraindication another antitnf biologic affiliation health insurance woman childbearing age must use appropriate mean contraception Pregnant breastfeed woman contraindication antitnf biologic patient know hypersensitivity excipients Severe uncontrolled opportunistic infection , includins septicemia , tuberculosis , abcess opportunistic infection Evolutive infection , include chronic localise infection Patient moderate severe heart failure ( NYHA class III/IV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>spondyloarthritis</keyword>
	<keyword>monoclonal antibody anti-TNF</keyword>
	<keyword>secondary treatment failure</keyword>
</DOC>